Exelixis Stock Price, News & Analysis (NASDAQ:EXEL)

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.

16 Wall Street analysts have issued twelve-month target prices for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they predict the company's stock price to reach $25.44 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.

Exelixis' stock was trading at $16.04 at the beginning of 2023. Since then, EXEL stock has increased by 37.2% and is now trading at $22.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our EXEL earnings forecast.

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by $0.07. The biotechnology company earned $471.90 million during the quarter, compared to the consensus estimate of $473.31 million. Exelixis had a net margin of 5.19% and a trailing twelve-month return on equity of 3.71%. The company's revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.23 EPS.

ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), IQ U.S. Mid Cap R&D Leaders ETF (MRND), SPDR S&P Biotech ETF (XBI) and Inspire Fidelis Multi Factor ETF (FDLS).

Exelixis updated its FY 2023 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.85 billion, compared to the consensus revenue estimate of $1.84 billion.

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Exelixis' stock is owned by a number of retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (1.07%), Jacobs Levy Equity Management Inc. (1.06%), Morgan Stanley (1.01%), Meditor Group Ltd (0.99%), Bank of New York Mellon Corp (0.96%) and FMR LLC (0.93%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Christopher J Senner, Dana Aftab, David Edward Johnson, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.